ImmunityBio, Inc. IBRX Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current)?
- ImmunityBio, Inc. (IBRX) reported allowance for doubtful accounts receivable (current) of $2.5M in Q1 2026.
- How has ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current) changed year-over-year?
- ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current) increased by 525.0% year-over-year, from $400K to $2.5M.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.